Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material.
Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992.
Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.
From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet
Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice.
Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.
Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.
Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.
Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material.
We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.
Find out about our current vacancies at Berlin-Chemie directly on our career portal.
Within the Menarini Group, Berlin-Chemie is the regional headquarters for the CEE and CIS region and is responsible for more than 30 countries and their local subsidiaries.
As a reliable partner in the healthcare sector, we want to use our products and expertise to help solve the complex challenges in the healthcare sector in these regions. To this end, Berlin-Chemie has established strong partnerships at all levels in many countries. We support doctors and patients with high-quality medical products and technologies to improve the quality of life.
BERLIN-CHEMIE AG
Glienicker Weg 125
12489 Berlin, Deutschland
E-mail: info@berlin-chemie.de
Phone: +49 (0)30 6707-0
Fax: +49 (0)30 6707-2120
2018 - 10 - 29
Florence, 29th October 2018 – The Menarini Assembly has decided to consolidate its Board of Directors appointing a new Board Member, Carlo Colombini, who will be joining recently appointed Chairman, Eric Cornut, and Board Members Lucia Aleotti, Alberto Giovanni Aleotti and Juerg Witmer.
Carlo Colombini brings with him a more than thirty- year experience in Menarini in both the pharmaceutical and chemical sectors and, taking on functions of ever-increasing responsibility, has reached the highest positions in the fields of Manufacturing and Logistics as well as Human Resources. Dr. Colombini has had a pivotal role in the decision making process for the investments made in manufacturing in both Italy and abroad and shall continue to have a significant role in the strategic plans for the future.
“I have had the opportunity to be part of an extraordinary project” stated Carlo Colombini, “which in the new millennium has seen the Menarini Group grow and develop from 10.000 employees to reach today’s 17.000, women and men who have contributed towards the Company’s success. We have accomplished our goal to make Menarini a solid and reliable player on an International level, a worldwide example of ‘Made in Italy’. We shall continue to make substantial investments in the R&D of new therapies with the ambition of finding a cure for hereunto unresolved diseases, and we have important projects in the field of cutting edge diagnostics as well as strengthening our international presence even further. In my new role as Board Member I shall do my utmost to make sure that we succeed in fulfilling the targets set.”